药物诱导心脏毒性(DICT)是药物试验失败和中止的主要原因。当前的心脏毒性药物标注主要关注个别结果或机制。考虑到广泛的心脏不良事件谱系，我们利用FDA标签开发了药物诱导心脏毒性排名(DICTrank)，并将1318种人用药分为四个类别：大部分DICT相关(341例)，较少DICT相关(528例)，无DICT相关(343例)和模糊DICT相关(106例)。值得注意的是，DICTrank涵盖了多种治疗类别，其中有几种富含大部分DICT相关的药物，如抗肿瘤药物、性激素、抗炎药物、β受体阻断剂和心脏疗法。DICTrank目前提供了最大的DICT标注药物清单，并且它在药物研发以及其他方面的DICT风险早期识别的新方法开发方面具有潜力。

Drug-induced cardiotoxicity (DICT) is a leading cause of drug trial failure and discontinuation. Current drug annotations for cardiotoxicity largely focus on individual outcomes or mechanisms. Considering the broad spectrum of adverse cardiac events, we developed Drug-Induced Cardiotoxicity Rank (DICTrank) using FDA labeling and comprehensively classified 1318 human drugs into four categories: Most-DICT-Concern (n=341), Less-DICT-Concern (n=528), No-DICT-Concern (n=343), and Ambiguous-DICT-Concern (n=106). Notably, DICTrank covers diverse therapeutic categories, of which several were enriched with Most-DICT-Concern drugs, such as antineoplastic agents, sex hormones, anti-inflammatory drugs, beta-blockers, and cardiac therapy. DICTrank currently presents the largest drug list of DICT annotation, and it could contribute to the development of new approach methods, including AI models for early identification of DICT risk during drug development and beyond.Published by Elsevier Ltd.